Arcus Historical Balance Sheet
RCUS Stock | USD 15.44 0.36 2.28% |
Trend analysis of Arcus Biosciences balance sheet accounts such as Other Liabilities of 456.4 M, Net Tangible Assets of 793.3 M, Property Plant And Equipment Net of 39.5 M or Accounts Payable of 10.8 M provides information on Arcus Biosciences' total assets, liabilities, and equity, which is the actual value of Arcus Biosciences to its prevalent stockholders. By breaking down trends over time using Arcus Biosciences balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Arcus Biosciences latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Arcus Biosciences is a good buy for the upcoming year.
Arcus Biosciences Inventory |
|
Arcus |
About Arcus Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Arcus Biosciences at a specified time, usually calculated after every quarter, six months, or one year. Arcus Biosciences Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Arcus Biosciences and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Arcus currently owns. An asset can also be divided into two categories, current and non-current.
Arcus Biosciences Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of Arcus Biosciences assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Arcus Biosciences books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Arcus Biosciences balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Arcus Biosciences are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Most accounts from Arcus Biosciences' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Arcus Biosciences current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Arcus Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. For more information on how to buy Arcus Stock please use our How to Invest in Arcus Biosciences guide.At this time, Arcus Biosciences' Property Plant Equipment is comparatively stable compared to the past year. Net Invested Capital is likely to gain to about 473.8 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 99.4 M in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 52.0M | 73M | 65M | 68.3M | Total Assets | 1.6B | 1.3B | 1.1B | 767.6M |
Arcus Biosciences balance sheet Correlations
Click cells to compare fundamentals
Arcus Biosciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Arcus Biosciences balance sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 203.1M | 772.3M | 1.6B | 1.3B | 1.1B | 767.6M | |
Other Current Liab | 1.5M | 31.4M | 52.0M | 73M | 65M | 68.3M | |
Total Current Liabilities | 22.7M | 121.7M | 166.1M | 193M | 184M | 99.4M | |
Total Stockholder Equity | 163.8M | 502.3M | 841.5M | 657M | 462M | 428.3M | |
Other Liab | 16.6M | 133.1M | 467.5M | 378M | 434.7M | 456.4M | |
Net Tangible Assets | 163.8M | 502.3M | 841.5M | 657M | 755.6M | 793.3M | |
Property Plant And Equipment Net | 9.3M | 23.6M | 137.4M | 35M | 51M | 39.5M | |
Net Debt | (57.9M) | (158.2M) | (31.0M) | (86M) | (116M) | (121.8M) | |
Retained Earnings | (205.3M) | (328.2M) | (275.4M) | (542M) | (849M) | (806.6M) | |
Accounts Payable | 4.7M | 15.7M | 10.3M | 20M | 17M | 10.8M | |
Cash | 57.9M | 173.4M | 147.9M | 206M | 127M | 130.2M | |
Non Current Assets Total | 10.4M | 37.2M | 910.6M | 278M | 264M | 211.7M | |
Non Currrent Assets Other | 872K | 7.2M | 591.2M | 114M | 106M | 113.0M | |
Other Assets | 1.1M | 25.7M | 10.7M | 14M | 16.1M | 8.5M | |
Cash And Short Term Investments | 188.3M | 735.1M | 681.3M | 1.1B | 759M | 554.5M | |
Net Receivables | 132K | 1.7M | 745M | 43M | 42M | 39.9M | |
Common Stock Shares Outstanding | 43.8M | 54.8M | 74.0M | 72M | 74M | 57.8M | |
Short Term Investments | 130.3M | 555.2M | 351.4M | 803M | 632M | 380.7M | |
Liabilities And Stockholders Equity | 203.1M | 772.3M | 1.6B | 1.3B | 1.1B | 767.6M | |
Non Current Liabilities Total | 16.6M | 148.3M | 584.4M | 495M | 449M | 239.9M | |
Capital Surpluse | 357.9M | 369.1M | 830.4M | 1.1B | 1.3B | 1.4B | |
Other Current Assets | 4.3M | 1M | 16M | 15M | 30M | 31.5M | |
Other Stockholder Equity | 369.1M | 830.4M | 1.1B | (7M) | (8.1M) | (7.6M) | |
Total Liab | 39.3M | 270.0M | 750.4M | 688M | 633M | 339.3M | |
Long Term Investments | 0.0 | 6.4M | 182.0M | 129M | 107M | 59.2M | |
Property Plant And Equipment Gross | 9.3M | 10.8M | 155.2M | 58M | 82M | 47.6M | |
Total Current Assets | 192.7M | 735.1M | 681.3M | 1.1B | 831M | 555.9M | |
Accumulated Other Comprehensive Income | 64K | 44K | (1.3M) | (7M) | (6.3M) | (6.0M) | |
Non Current Liabilities Other | 806K | 148.3M | 584.4M | 140M | 142M | 140.0M | |
Property Plant Equipment | 9.3M | 10.8M | 32.5M | 135M | 155.3M | 163.0M | |
Current Deferred Revenue | 7M | 74.6M | 102.0M | 97M | 91M | 60.2M | |
Deferred Long Term Liab | 15.8M | 3.2M | 4M | 3M | 2.7M | 2.6M | |
Net Invested Capital | 163.8M | 502.3M | 841.5M | 657M | 462M | 473.8M | |
Net Working Capital | 170.0M | 614.1M | 1.1B | 874M | 647M | 598.2M | |
Short Term Debt | 9.5M | 27.9M | 53.8M | 3M | 11M | 18.0M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arcus Stock Analysis
When running Arcus Biosciences' price analysis, check to measure Arcus Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcus Biosciences is operating at the current time. Most of Arcus Biosciences' value examination focuses on studying past and present price action to predict the probability of Arcus Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcus Biosciences' price. Additionally, you may evaluate how the addition of Arcus Biosciences to your portfolios can decrease your overall portfolio volatility.